ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.

CONCLUSION: Using the ASCO value framework, we constructed value snapshots of three major frontline therapeutic options in ovarian cancer. Dose-dense paclitaxel provided the highest additional value when analysis accounted for NHB and cost. However, additional research is needed to include individual patient preferences and provide personalized value assessments. PMID: 29016225 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29016225?dopt=Abstract

Source: JOP - October 10, 2017 Category: Gastroenterology Authors: Foote J, Secord AA, Liang M, Cohn DE, Jewell E, Havrilesky LJ Tags: J Oncol Pract Source Type: research